Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety study of GV-971 capsules in mild to moderate Alzheimer's disease
CTR20210760Phase 4Active
- Sponsor
- Green Valley
- Start
- Jun 2021
- Modality
- Microbiome-Derived Products → Microbiome Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of sodium oligomannate in Alzheimer's disease (AD), sponsored by Green Valley. Started Jun 2021; status: active.
02
Drugs
sodium oligomannate
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on CTR20210760.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210760.